Simple Summary Triple Negative Breast Cancer (TNBC) comprises approximately 15–20%
of all breast cancer (BC) cases, is often diagnosed at an advanced stage, and is generally …

Simple Summary Cancer treatments have made remarkable advances with the introduction
of immunotherapy, which recruits the body's immune system to fight cancer. Despite these …

Bone metastasis (BM) is a frequent complication associated with advanced cancer that
significantly increases patient mortality. Myeloid-derived suppressor cells (MDSCs) play a …

With the rapid development of tumor immunotherapy, nanoparticle vaccines have attracted
much attention as potential therapeutic strategies. A systematic review and analysis must be …

Considering the unfavourable response of breast cancer (BC) to treatment, we assessed the
therapeutic potential hesperidin in mice bearing 4T1 BC tumours. Anti‐tumour effects were …

Patients with triple negative breast cancer (TNBC) show only modest response rates to
immune checkpoint inhibitor immunotherapy, motivating ongoing efforts to identify …

The rapid expansion of cancer immunology and immunotherapy builds upon the success of
early immune checkpoint inhibitors (ICI) and chimeric antigen receptor T cells for some …

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer
characterized by the absence of progesterone and estrogen receptors and low (or absent) …

The immune background of breast cancer is highly heterogeneous and the immune system
of the human body plays a dual role by both promoting and suppressing its progression …

Triple-negative breast cancer (TNBC) is known as a refractory and inoperable breast cancer
subtype with the worst prognosis. The poor treatment response due to the lack of specific …